PARIS and NEW YORK, Dec. 28 /PRNewswire-FirstCall/ -- Sanofi-aventis
(Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers
Squibb (New York: NYSE: BMY) announced today that the Canadian Federal
Court of Appeals dismissed Apotex Inc.'s ("Apotex") appeal of the judgment
of the Federal Court of Canada prohibiting the Minister of Health from
issuing a Notice of Compliance to Apotex in connection with its 75mg
clopidogrel bisulfate tablets. Absent a Notice of Compliance, Apotex cannot
market its 75mg clopidogrel bisulfate tablets in Canada.
About sanofi-aventis
Sanofi-aventis is the world's third largest pharmaceutical company,
ranking number one in Europe. Backed by a world-class R&D organization,
sanofi-aventis is developing leading positions in seven major therapeutic
areas: cardiovascular, thrombosis, oncology, metabolic diseases, central
nervous system, internal medicine, and vaccines.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global pharmaceutical and related health care
products company whose mission is to extend and enhance human life.
SOURCE Sanofi-aventis; Bristol-Myers Squibb
 back to top
Related links:
http://www.bms.com
CONTACT:
MEDIA: Jean-Marc Podvin, +33-1-53-77-42-23,
jean-marc.podvin@sanofi-aventis.com, or INVESTORS: Sanjay Gupta,
+33-1-53-77-45-45, sanjay.gupta@sanofi-aventis.com, both of
sanofi-aventis; or MEDIA: Laura Hortas, +1-609-252-4587,
laura.hortas@bms.com, or INVESTORS: John Elicker,
+1-212-546-3775, john.elicker@bms.com, both of Bristol-Myers
Squibb
|
